Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus
Autore:
Trotter, JF; Wachs, ME; Trouillot, TE; Bak, T; Kugelmas, M; Kam, I; Everson, G;
Indirizzi:
Univ Colorado, Hlth Sci Ctr, Div Gastroenterol Hepatol, Denver, CO 80262 USA Univ Colorado Denver CO USA 80262 roenterol Hepatol, Denver, CO 80262 USA Univ Colorado, Hlth Sci Ctr, Div Transplant Surg, Denver, CO 80262 USA Univ Colorado Denver CO USA 80262 v Transplant Surg, Denver, CO 80262 USA
Titolo Testata:
LIVER TRANSPLANTATION
fascicolo: 5, volume: 7, anno: 2001,
pagine: 401 - 408
SICI:
1527-6465(200105)7:5<401:DDSTIL>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMPLICATIONS; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Trotter, JF Univ Colorado, Hlth Sci Ctr, Div Gastroenterol Hepatol, 4200 E9th Ave,B-154, Denver, CO 80262 USA Univ Colorado 4200 E 9th Ave,B-154 Denver CO USA 80262 262 USA
Citazione:
J.F. Trotter et al., "Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus", LIVER TRANS, 7(5), 2001, pp. 401-408

Abstract

Since its approval as an immunosuppressive agent in renal transplantation,sirolimus (RAPA) recently has been used in the primary immunosuppression regimen at several liver transplant centers, One of the major side effects of RAPA is hypercholesterolemia, which is reported in up to 44% of patients,We describe our experience in 57 primary liver transplant recipients treated with RAPA and either cyclosporine A (CSA) or tacrolimus (TAC), We reportthe incidence and severity of hypercholesterolemia using a prednisone-freeimmunosuppressive regimen, Between January 2000 and September 2000, a total of 57 patients underwent transplantation at the University of Colorado Health Sciences Center (Denver, CO) with RAPA and either CSA or TAG. The initial 10 patients who underwent transplantation under this protocol were not administered corticosteroids, and the subsequent 47 patients were administered only 3 doses of methylprednisolone days 0, 1, and 2 postoperatively (1,0.5, and 0.5 g, respectively). Total fasting cholesterol, high-density cholesterol, low-density cholesterol, and triglyceride levels were measured at monthly intervals. Mean serum cholesterol level was significantly greater in CSA patients (200 mg/dL) compared with TAC patients (158 mg/dL; P =,0003), Serum triglyceride levels were more than 2-fold greater with CSA (292 mg/dL) compared with TAC (134 mg/dL; P=.002), Hypercholesterolemia (cholesterol > 240 mg/dL) was present in 10 of 57 patients (18%) and was significantlymore common in CSA-treated patients (8 of 27 patients; 30%) compared with TAG-treated patients (2 of 30 patients; 6%; P < ,05), Hypertriglyceridemia (serum triglyceride > 300 mg/dL) was present in 10 of 57 patients (18%) andwas significantly more common in CSA-treated patients (9 of 27 patients; 33%) compared with TAG-treated patients (1 of 30 patients; 3%; P <,05). We conclude that (1) concomitant use of TAC with RAPA reduces the prevalence and severity of posttransplantation dyslipidemia, and (2) these findings haveimportant implications in the prevention of complications of hypercholesterolemia in liver transplant recipients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 12:17:02